Cadrenal Therapeutics
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2022-01-01
- Employees
- 4
- Market Cap
- $429.1K
- Website
- http://www.cadrenal.com
- Introduction
Cadrenal Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focused on developing novel therapy. It develops tecarfarin, a novel therapy with orphan drug indication, designed for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was founded by Quang ...
CADRENAL THERAPEUTICS HIGHLIGHTS PRESENTATION AT EUROPEAN ...
Cadrenal Therapeutics presented tecarfarin data and a proposed clinical trial protocol at the 8th EACTS Mechanical Circulatory Support Summit, aiming to evaluate tecarfarin versus warfarin in Abbott HeartMate3 LVAD patients. Dr. Mandeep R. Mehra highlighted tecarfarin's potential to improve time in therapeutic range (TTR) and reduce bleeding events in advanced heart failure patients requiring chronic anticoagulation.
Cadrenal's Tecarfarin Shows Promise for LVAD Patients in Key Medical Congress Data
Cadrenal Therapeutics presented tecarfarin data and proposed clinical trial protocol at the 8th EACTS Mechanical Circulatory Support Summit, aiming to evaluate tecarfarin versus warfarin in Abbott HeartMate3 LVAD patients, with potential to improve time in therapeutic range (TTR) and reduce bleeding events.
CVKD: New Blood Thinner Ready for Phase 3; Initiating Coverage of Cadrenal Therapeutics, Inc
Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) is developing tecarfarin, a novel oral anticoagulant for cardiovascular and renal diseases, with a $30.00 valuation. Tecarfarin aims to address unmet needs in patients with LVADs, ESKD+AFib, and mechanical heart valves. The drug has received FDA Orphan Drug Designation and Fast Track status, with potential peak sales of $900 million for LVADs and $600 million for ESKD+AFib.
© Copyright 2024. All Rights Reserved by MedPath